Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT07022587

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07022587
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07022587. Randomized; single masking; primary purpose treatment. Start 2025-12-20 (actual); primary completion 2030-12-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions
Acronym
REC-CAGEFREE Ⅳ
Condition
De Novo Stenosis
Intervention (Device)
Sirolimus-eluting bioresorbable scaffolds
Intervention (Device)
Sirolimus-eluting stents
Lead sponsor
Xijing Hospital (class: other)

Record details

Record id
cardio:ct-nct07022587
Content hash
61bdefdd57a4634931b3285e2a51d2a40677253f4c99b81552bdcb2f415870a9